This transcript has been edited for clarity. Gayatri Acharya, MD: Greetings. I'm Dr Gayatri Acharya, cardiology fellow at Mayo Clinic. During today's roundtable, we'll be discussing cardiac ...
CLEVELAND, Ohio – First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients ...
Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the ...
An amyloidosis diagnosis can take upwards of 2 years.Initial symptoms often are nondescript, and irreversible organ damage frequently occurs before disease confirmation.
Immix Biopharma reported successful dosing of six patients in its Phase 1b trial for the CAR-T therapy NXC-201. The press release acknowledges that no drugs are currently FDA approved for patients ...
Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...
LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...
Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in patients ...
ZURICH, Dec. 4, 2025 /PRNewswire/ -- Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results